Want to Live as Long as an Olympian? Become a Chess Grandmaster

Kena Betancur, AFP/Getty Images
Kena Betancur, AFP/Getty Images

It’s well known that physical fitness can help prolong your life, so it’s not surprising that elite athletes, like Olympians, tend to have longer lifespans than your average couch potato. But it seems that “mind sports” can help keep you alive longer, too. According to BPS Research Digest, a recent study suggests that international chess grandmasters have lifespans comparable to Olympic athletes.

The study, published in PLOS ONE, examined the survival rates of 1208 mostly male chess grandmasters and 15,157 Olympic medalists from 28 countries, and analyzed their life expectancy at 30 years and 60 years after they attained their grandmaster titles. They found that both grandmasters and Olympic medalists exhibited significant lifespan advantages over the general population. In fact, there was no statistical difference between the relative survival rates of chess champions and athletic champions.

There are several variables that the study couldn’t take into account that may be linked to chess players’ long lifespans, though. Grandmasters often employ nutritionists and physical trainers to keep them at their best, according to the researchers, and exercise regularly. Economic and social status can also influence lifespans, and becoming a world-champion chess player likely results in a boost in both areas.

Some research has shown that keeping your mind sharp can help you in old age. Certain kinds of brain training might lower the risk of developing dementia, and one study found that board game players in particular have slightly lower rates of dementia.

If keeping the mind sharp with chess really does extend lifespans, the same effect might apply as well to elite players of other “mind sports,” like Go, poker, or competitive video games. We’ll need more research to find out.

[h/t BPS Research Digest]

FDA Recalls Thyroid Medications Due to Contamination Risk

iStock
iStock

Hypothyroid medications manufactured by Westminster Pharmaceuticals have been recalled after it was discovered that one of the company’s Chinese suppliers failed to meet U.S. Food and Drug Administration (FDA) standards, CNN reports.

The oral tablets contain levothyroxine (LT4) and liothyronine (LT3), which are both synthetic hormones used to treat thyroid conditions.

The medicine was recalled as a precaution after it was discovered during a 2017 FDA inspection that the Chinese supplier in question, Sichuan Friendly Pharmaceutical Co., was not practicing good manufacturing practices.

However, patients with serious thyroid conditions shouldn’t throw out their pills just yet. No adverse effects from the medication have been reported, and the risk of not taking the medication outweighs the risk of taking a recalled pill.

According to the FDA, “Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product.”

For more information on the specific lots and products in question, visit the FDA’s website.

[h/t CNN]

A 'Zombie Gene' Might Be the Reason Elephants Rarely Get Cancer

iStock
iStock

When it comes to cancer rates in the animal kingdom, elephants are an anomaly. As Popular Science notes, cancer should be more common among larger species, but with elephants, that simply isn’t the case. Only about 5 percent of elephants die from cancer, compared to 11 to 25 percent of humans.

In a new study, published in Cell Reports, University of Chicago researchers found what’s believed to be the genetic source of elephants’ cancer immunity. Elephants, like all mammals, have a gene called LIF that is known to suppress tumors. Humans have one copy of this gene, but elephants have 10 copies, which have developed over 80 million years of evolution. However, only one of those copies, called LIF6, is functional in elephants.

The other LIF copies are essentially dead because they lack a specific piece of DNA to make them function. At some point during the evolutionary process, the LIF6 gene copy turned back on, but scientists don’t know why or when this occurred. This “zombie gene” helps kill mutated cells, in true Night of the Living Dead fashion.

“This reanimation of LIF6 occurred perhaps over 59 million years,” Joshua Schiffman, who studies cancer in elephants but was not involved in the study, told Popular Science. “That’s an amazingly long period of time for nature to modify and perfect an anticancer mechanism.”

Scientists aren’t yet sure how this could be applied to cancer research in humans, but they say it’s a promising start and a creative approach to the problem. While these findings are still fresh and need to be duplicated, it raises the possibility of creating a drug that mimics the function of LIF6.

[h/t Popular Science]

SECTIONS

arrow
LIVE SMARTER
More from mental floss studios